论文部分内容阅读
一项考察RAS野生型和KRAS野生型化疗耐药的转移性结直肠癌患者在最佳支持治疗中加入帕尼单抗的疗效的Ⅲ期研究结果显示,加入帕尼单抗可以显著改善患者总生存、无进展生存及客观缓解率。
A phase III study examining the efficacy of panitumumab in optimal supportive care in patients with metastatic colorectal cancer resistant to RAS wild-type and KRAS wild-type chemoresistance showed that addition of panitumumab significantly improved overall patient response Survival, progression-free survival and objective response rates.